| __timestamp | Biogen Inc. | Summit Therapeutics Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2232342000 | 6795238 |
| Thursday, January 1, 2015 | 2113100000 | 7454247 |
| Friday, January 1, 2016 | 1947900000 | 10345862 |
| Sunday, January 1, 2017 | 1935500000 | 16984203 |
| Monday, January 1, 2018 | 2106300000 | 16187290 |
| Tuesday, January 1, 2019 | 2374700000 | 9299233.54 |
| Wednesday, January 1, 2020 | 2504500000 | 19232000 |
| Friday, January 1, 2021 | 2674300000 | 23611000 |
| Saturday, January 1, 2022 | 2403600000 | 26700000 |
| Sunday, January 1, 2023 | 2549700000 | 28215000 |
| Monday, January 1, 2024 | 2403700000 |
Igniting the spark of knowledge
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Biogen Inc. and Summit Therapeutics Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. Biogen, a giant in the biotech sector, has consistently invested heavily in SG&A, with expenses peaking at approximately $2.67 billion in 2021, marking a 38% increase from 2014. This reflects Biogen's aggressive market expansion and operational strategies. In contrast, Summit Therapeutics, a smaller player, has seen its SG&A expenses grow from around $6.8 million in 2014 to nearly $28 million in 2023, a staggering 312% increase. This surge indicates Summit's strategic push to enhance its market presence. These trends highlight the diverse approaches companies take to navigate the ever-evolving pharmaceutical landscape.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Biogen Inc.
SG&A Efficiency Analysis: Comparing Novartis AG and Biogen Inc.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Biogen Inc.
Biogen Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
Biogen Inc. and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Summit Therapeutics Inc. vs Alpine Immune Sciences, Inc.
Who Optimizes SG&A Costs Better? Summit Therapeutics Inc. or Catalyst Pharmaceuticals, Inc.
Summit Therapeutics Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and Vericel Corporation
Summit Therapeutics Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Evotec SE